Advertisement

Advertisement

ADVERTISEMENT

Quality Outlook

Quality Outlook

We Need Better Quality Measures for Oncology Care First

01/24/2020

Manasi A. Tirodkar , PhD, MS;

David Blaisdell , BA;

Tom Valuck , MD, JD;

Tom Valuck, MD, JD, and colleagues of Discern Health, part of Real Chemistry, argue that if the Oncology Care First model proposed by CMS is adopted as proposed, CMS will be missing a critical opportunity to advance quality measurement for...

Tom Valuck, MD, JD, and colleagues of Discern Health, part of Real Chemistry, argue that if the Oncology Care First model proposed by CMS is adopted as proposed, CMS will be missing a critical opportunity to advance quality measurement for...

Tom Valuck, MD, JD, and...

01/24/2020

Journal of Clinical Pathways

Quality Outlook

Catch Me If You Can: Aligning Quality Measurement With Oncology Innovation

11/22/2019

David Blaisdell , BA;

Tom Valuck , MD, JD;

Theresa Schmidt , MA, PMP, CSPO;

Tom Valuck, MD, JD, and colleagues of Discern Health, part of Real Chemistry, highlight the challenge that physicians face with integrating rapid science advances into practice while payers pressure them to improve value.

Tom Valuck, MD, JD, and colleagues of Discern Health, part of Real Chemistry, highlight the challenge that physicians face with integrating rapid science advances into practice while payers pressure them to improve value.

Tom Valuck, MD, JD, and...

11/22/2019

Journal of Clinical Pathways

Quality Outlook

Oncology Quality Measurement: Angst and Ambition

09/18/2019

Tom Valuck , MD, JD;

Manasi A. Tirodkar , PhD, MS;

David Blaisdell , BA;

In the first installment of the Quality Outlook commentary series, Tom Valuck, MD, JD, Discern Health, part of Real Chemistry, and colleagues assert the need for value-based solutions and adequate value assessment measurements to ensure that...

In the first installment of the Quality Outlook commentary series, Tom Valuck, MD, JD, Discern Health, part of Real Chemistry, and colleagues assert the need for value-based solutions and adequate value assessment measurements to ensure that...

In the first installment of the...

09/18/2019

Journal of Clinical Pathways

Breakthrough treatments in health care are driving rapid changes in the definitions of quality and value. This is especially true in oncology, where innovations like cell and gene therapies and AI-powered diagnostics are rapidly changing care pathways.

Efforts to implement value-based care models in oncology and beyond must meet the demands of evolving science, emerging technology, new care practices, and shifting patient priorities. Quality measures must be up-to-date and relevant. Payment models must recognize the challenges and costs of managing complex patient populations with diverse needs.

In this JCP commentary series, Quality Outlook, Real Chemistry will explore key issues in quality and value through posts focused on measurement, value-based payment, and quality improvement.

Real Chemistry’s mission is to transform what health care is to what it should be by leveraging the industry’s most advanced AI-powered insights, diverse expertise, and customer-centric ideas. The organization helps the health care industry better understand, reach, and engage patients and professionals—while creating healthcare experiences that span diagnosis to adherence—enabling clients to meet and exceed their potential.

Tom Valuck, MD, JD, is the editor of Quality Outlook and leader of the Market Access Value-Based Care discipline. The Market Access team at Real Chemistry uses research and strategic advisory services to help our clients improve health and health care by assessing, responding to, and shaping the value landscape.

Tom is a thought leader on health care system transformation and helps drive Real Chemistry’s focus on achieving better health and health care outcomes at a lower cost. Tom’s work includes facilitating the exploration of next-generation measurement and accountability models for health care delivery systems. He also helps clients develop strategies to achieve success within the value-based marketplace.

Advertisement

Advertisement

Advertisement